- Home
- ADXN vs RDHL Comparison
ADXN vs RDHL Comparison
Compare ADXN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- RDHL
- Stock Information
- Founded
- ADXN 2002
- RDHL 2009
- Country
- ADXN Switzerland
- RDHL Israel
- Employees
- ADXN N/A
- RDHL N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- RDHL Health Care
- Exchange
- ADXN Nasdaq
- RDHL Nasdaq
- Market Cap
- ADXN 8.0M
- RDHL 8.2M
- IPO Year
- ADXN N/A
- RDHL N/A
- Fundamental
- Price
- ADXN $7.59
- RDHL $5.85
- Analyst Decision
- ADXN Strong Buy
- RDHL
- Analyst Count
- ADXN 1
- RDHL 0
- Target Price
- ADXN $30.00
- RDHL N/A
- AVG Volume (30 Days)
- ADXN 24.5K
- RDHL 11.0K
- Earning Date
- ADXN 03-24-2025
- RDHL 08-29-2024
- Dividend Yield
- ADXN N/A
- RDHL N/A
- EPS Growth
- ADXN N/A
- RDHL N/A
- EPS
- ADXN 0.06
- RDHL N/A
- Revenue
- ADXN $701,260.00
- RDHL $3,707,000.00
- Revenue This Year
- ADXN N/A
- RDHL $224.90
- Revenue Next Year
- ADXN N/A
- RDHL $82.69
- P/E Ratio
- ADXN $1.04
- RDHL N/A
- Revenue Growth
- ADXN N/A
- RDHL N/A
- 52 Week Low
- ADXN $6.81
- RDHL $5.41
- 52 Week High
- ADXN $27.90
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- ADXN 48.97
- RDHL 40.41
- Support Level
- ADXN $7.20
- RDHL $5.80
- Resistance Level
- ADXN $8.04
- RDHL $6.26
- Average True Range (ATR)
- ADXN 0.51
- RDHL 0.31
- MACD
- ADXN 0.00
- RDHL 0.01
- Stochastic Oscillator
- ADXN 47.95
- RDHL 19.33
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.